ArticleGynecologic oncology2020
Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma.
Article in Gynecologic oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Survival outcomes in IIIC cervical cancer by treatment strategies: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Working in concert: radiology, pathology, and gynecologic oncology applications of the 2023 FIGO updates in endometrial cancer staging.Abdominal radiology (New York) · 2026Review
- Decoding the 2023 FIGO Staging System in Endometrial Cancer: A Practical, Visually Guided Framework for Molecular Risk-Adapted Care Incorporating the 2025 Risk Group Update.Current oncology reports · 2026Review
- Updates and evolving care paradigms for pre-menopausal patients with endometrial cancer.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026Review
- Development and Validation of a Prognostic Nomogram for Endometrial Cancer Based on Systemic Immune-Inflammation Index and Key Clinicopathological Features.Cancer management and research · 2026Article
- Sentinel lymph node distribution in endometrial cancer: clinical patterns and implications from a 292-patient cohort.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026Article
- Probabilistic mapping of lymph node metastasis in epithelial ovarian cancer: a retrospective cohort study using Bayesian network analysis.Frontiers in oncology · 2026Article
- The past, present, and future of FIGO staging of endometrial cancer.Journal of gynecologic oncology · 2025Review
- New FIGO 2023 Staging System of Endometrial Cancer: An Updated Review on a Current Hot Topic.Geburtshilfe und Frauenheilkunde · 2025Article
- Lymph node metastases in endometrial carcinoma: A modern assessment in the era of sentinel lymph node mapping and molecular subtyping.Gynecologic oncology · 2024Article
- Screening of prognostic factors and survival analysis based on histological type for perimenopausal endometrial carcinoma treated with hysterectomy.Discover oncology · 2024Article
- New clinicopathological concept of endometrial carcinoma with integration of histological features and molecular profiles.Pathology international · 2024Review
- Article
- Review
- Prognosis of isolated tumor cells and use of molecular classification in early stage endometrioid endometrial cancer.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024Article
- Review
- Impact of the 2023 FIGO Staging System for Endometrial Cancer on the Use of Imaging Services: An Indian Perspective.The Indian journal of radiology & imaging · 2024Review
- Low-Volume Metastases in Apparent Early-Stage Endometrial Cancer: Prevalence, Clinical Significance, and Future Perspectives.Cancers · 2024Review
- Advancing Tailored Treatments: A Predictive Nomogram, Based on Ultrasound and Laboratory Data, for Assessing Nodal Involvement in Endometrial Cancer Patients.Journal of clinical medicine · 2024Article
- Is fluorometric sentinel lymph node biopsy in endometrial cancer necessary?Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveWe report the incidence of occult nodal metastasis in patients who underwent primary surgical staging for apparent early endometrioid or serous endometrial cancer with bilateral SLN mapping and enhanced pathology. Occult ovarian metastasis rates were also reported.
methodsPatients with clinical stage I serous or endometrioid endometrial cancer who underwent primary staging surgery with successful bilateral SLN mapping from 1/2005-12/2018 were retrospectively evaluated. Rates of isolated tumor cells (ITCs), micro- and macrometastatic nodal disease, and occult ovarian involvement were reported.
resultsOf 1044 patients, 959 had endometrioid and 85 serous carcinoma. There were no positive SLNs among 510 patients with noninvasive FIGO grade 1/2 endometrioid carcinoma and < 1%ITCs. Grade 1: 4.5%(9/202) with inner-half and 10%(6/62) with outer-half myoinvasion had positive SLNs. Grade 2: rates were 4%(3/76) and 20%(8/41), respectively. Grade 3: 5%(1/20) with noninvasive, 3%(1/31) with inner-half, and 24%(4/17) with outer-half myoinvasion had positive SLNs. ITC incidence increased with depth of myoinvasion-25% of deeply invasive grade 1/2 and 18% of deeply invasive grade 3 tumors. Four (10%) of 41 patients with noninvasive serous endometrial carcinoma had ITCs or positive SLNs. There were no occult ovarian metastases with grades 1/2 disease, 2/68 (3%) with grade 3 disease, and 2/85 (2%) with serous endometrial carcinoma.
conclusionUltrastaging SLNs may be unwarranted in low-grade noninvasive endometrioid cancer but valuable in noninvasive serous carcinoma. Occult ovarian metastasis is uncommon in early endometrial carcinoma and occurs in 2-3% of high-risk histologies. Further research is needed to determine ITC significance, particularly with regard to adjuvant treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.